Contribute Try STAT+ Today

Hello, everyone, and how are you today? We are doing just fine, thank you, helped along by a shiny sun enveloping the otherwise chilly Pharmalot campus. A few cups of stimulation can also be useful, we are the first to confess. Meanwhile, we are as busy as ever, foraging for interesting items. On that note, here are a few tidbits to help you on your own journey. We hope all goes well today and that you conquer the world. And as always, do keep in touch. We appreciate your insights …

A Food and Drug Administration advisory panel overwhelmingly voted to approve an Amgen (AMGN) osteoporosis treatment for postmenopausal women at high risk for fracture, Reuters reports. The panel voted 16-1 in favor of the monthly injection developed jointly with UCB. The drug, Evenity, helps reduce the risk of fracture by increasing bone formation and inhibiting breakdown of bone minerals. However, the panel raised concerns about cardiovascular safety risks linked to the drug, which FDA staff reviewers had cited as the main reason for convening the panel meeting.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.